Literature DB >> 7610586

The effect of vasoactive intestinal peptide on development of form deprivation myopia in the chick: a pharmacological and immunocytochemical study.

R L Seltner1, W K Stell.   

Abstract

The role of vasoactive intestinal peptide (VIP) in the development of form deprivation myopia (FDM) was examined. Daily intravitreal injection of porcine VIP reduced, but did not eliminate FDM at a maximal daily dose of 1 x 10(-5) mol/injection. A VIP analogue reported to be relatively hydrolysis-resistant in vivo, had no effect on development of FDM at any dose tested. Two VIP antagonists completely abolished FDM. The one reported to be selective for central nervous system VIP receptors was 100 times more potent than one reported to be selective for peripheral nervous system receptors (ED50 = 2 x 10(-10) and 2 x 10(-8) mol/injection respectively). By immunofluorescence using antiserum to porcine VIP, VIP-like immunoreactivity was localized to a subset of amacrine cells (AC) and in three parallel layers in the inner plexiform layer (IPL) (10%, 40% and 70% of IPL thickness from the AC layer). Immunoreactive nerve fibres were also seen in the choroid, the ciliary body and the iris. These results suggest that VIP may play a role in both normal development of the refractive properties of the eye, and in the development of FDM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7610586     DOI: 10.1016/0042-6989(94)00244-g

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  26 in total

1.  The hyperopic effect of narrow-band long-wavelength light in tree shrews increases non-linearly with duration.

Authors:  Alexander H Ward; Thomas T Norton; Carrie E Huisingh; Timothy J Gawne
Journal:  Vision Res       Date:  2018-04-26       Impact factor: 1.886

Review 2.  Gene profiling in experimental models of eye growth: clues to myopia pathogenesis.

Authors:  Richard A Stone; Tejvir S Khurana
Journal:  Vision Res       Date:  2010-04-02       Impact factor: 1.886

3.  Image defocus and altered retinal gene expression in chick: clues to the pathogenesis of ametropia.

Authors:  Richard A Stone; Alice M McGlinn; Donald A Baldwin; John W Tobias; P Michael Iuvone; Tejvir S Khurana
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

Review 4.  IMI - Report on Experimental Models of Emmetropization and Myopia.

Authors:  David Troilo; Earl L Smith; Debora L Nickla; Regan Ashby; Andrei V Tkatchenko; Lisa A Ostrin; Timothy J Gawne; Machelle T Pardue; Jody A Summers; Chea-Su Kee; Falk Schroedl; Siegfried Wahl; Lyndon Jones
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-02-28       Impact factor: 4.799

5.  Altered gene expression in tree shrew retina and retinal pigment epithelium produced by short periods of minus-lens wear.

Authors:  Li He; Michael R Frost; John T Siegwart; Thomas T Norton
Journal:  Exp Eye Res       Date:  2018-01-09       Impact factor: 3.467

6.  Glucagon receptor agonists and antagonists affect the growth of the chick eye: a role for glucagonergic regulation of emmetropization?

Authors:  Kirstan A Vessey; Kathy A Lencses; David A Rushforth; Victor J Hruby; William K Stell
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-11       Impact factor: 4.799

7.  Pharmaceutical intervention for myopia control.

Authors:  Prema Ganesan; Christine F Wildsoet
Journal:  Expert Rev Ophthalmol       Date:  2010-12-01

Review 8.  Pharmacology of myopia and potential role for intrinsic retinal circadian rhythms.

Authors:  Richard A Stone; Machelle T Pardue; P Michael Iuvone; Tejvir S Khurana
Journal:  Exp Eye Res       Date:  2013-01-08       Impact factor: 3.467

9.  A microarray analysis of retinal transcripts that are controlled by image contrast in mice.

Authors:  Christine Brand; Frank Schaeffel; Marita Pauline Feldkaemper
Journal:  Mol Vis       Date:  2007-06-18       Impact factor: 2.367

10.  Microarray analysis of retinal gene expression in Egr-1 knockout mice.

Authors:  Ruth Schippert; Frank Schaeffel; Marita Pauline Feldkaemper
Journal:  Mol Vis       Date:  2009-12-10       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.